Amlodipine And Atorvastatin Tablet, Film Coated
Product Images NDC 72162-2094

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Amlodipine And Atorvastatin (NDC 72162-2094). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Amlodipine Besylate And Atorvastatin Calcium 02)

A line graph depicting event rate over time (months) comparing two groups: Placebo and Amlodipine. The graph shows cumulative event rates increasing over 24 months, with the Amlodipine group consistently having a lower event rate than the Placebo group. The chart includes statistical annotations with a p-value of 0.003, a hazard ratio of 0.691, and a 95% confidence interval of 0.54 to 0.88. The number of subjects at risk is displayed along the horizontal axis.*

FDA Label Image

Figure 2 (Amlodipine Besylate And Atorvastatin Calcium 03)

A forest plot presenting hazard ratios with 95% confidence intervals comparing Amlodipine treatment to placebo across multiple patient subgroups. The chart includes overall patient data and stratifications by age, gender, baseline sitting systolic blood pressure, baseline vessel disease, vessels with stenosis, and PCI-stent status. The x-axis represents the hazard ratio scale from 0 to 2, with a vertical line at 1 indicating no effect.*

FDA Label Image

Figure 3 (Amlodipine Besylate And Atorvastatin Calcium 04)

A line graph showing cumulative incidence percentages over time in years for two groups: Atorvastatin and placebo. The graph includes a hazard ratio (HR) of 0.64 with a 95% confidence interval (0.50-0.83) and a p-value of 0.0005, indicating statistical comparison between the groups.*

FDA Label Image

Figure 4 (Amlodipine Besylate And Atorvastatin Calcium 05)

A line chart comparing the cumulative hazard percentage over time in years for Atorvastatin versus a placebo. The x-axis represents time to the first primary endpoint up to four years of follow-up, and the y-axis shows cumulative hazard percentage. The chart includes hazard ratio and p-value information.*

FDA Label Image

Figure 5 (Amlodipine Besylate And Atorvastatin Calcium 06)

A line graph comparing subjects experiencing a major cardiovascular event over time, showing two groups for Atorvastatin 10 mg and Atorvastatin 80 mg. The x-axis indicates time to the first major cardiovascular endpoint in years, and the y-axis shows the percentage of subjects experiencing the event. The graph includes hazard ratio data (HR 0.78) with confidence intervals and a p-value.*

FDA Label Image

Amlodipine (Amlodipine)

Chemical structure diagram showing molecular formulas and bonds for Amlodipine and Atorvastatin components, including aromatic rings and functional groups. The image depicts the arrangement of chemical groups such as chlorine, sulfur dioxide (SO3H), and amine side chains.*

FDA Label Image

Atorvastatin-glycol-solvate (Atorvastatin Glycol Solvate)

Chemical structure of amlodipine and atorvastatin, showing the molecular arrangement of the active ingredients in the medication, including calcium ions and associated molecular groups.*

FDA Label Image

Label (Lbl721622094)

Label for Amlodipine and Atorvastatin Tablets, USP, 5 mg/40 mg film-coated tablets. The label indicates a package containing 30 tablets, relabeled by Bryant Ranch Prepack, Inc., Burbank, CA, and manufactured by Apotex Inc. Storage instructions and a caution to keep medication out of reach of children are also visible.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.